Plasma-derived products have a non-negligible position in the Chinese pharmaceutical field

Plasma-derived products have a non-negligible position in the Chinese pharmaceutical field
In China’s pharmaceutical market, plasma-derived products is a relatively special pharmaceutical species, because the plasma-derived products industry is a relatively low degree of marketization and subject to strong policy control of a pharmaceutical industry. This is due to its product characteristics because plasma derivatives are extracted from the human body and fresh plasma has to go through a series of processes before the final production of blood preparations, any one of which may lead to contamination of the plasma products, so China’s plasma-derived products are less marketed, but this does not mean that China’s plasma-derived products in China’s pharmaceutical market is also low status.
Like other finished pharmaceutical products in China, the plasma-derived product industry also has its own industry chain. The upstream of China’s plasma-derived product industry chain is the plasma collection station, which is the blood collection station for blood donors; the midstream of China’s plasma derivatives industry chain is the various blood product manufacturers and processors, which are represented by Pharmacare Technology Co.; Downstream of China’s plasma-derived products industry chain is the demand side of blood preparation, mainly medical institutions and major hospitals within China and globally. 
The high status of plasma-derived products in Chinese pharmaceutical market is reflected in their wide applicability. It is well known that plasma-derived product have a wide range of indications and are effective in the prevention and treatment of major diseases. As a substitute for blood, plasma-derived products can not be replaced by other drugs or medicines and have a long self life for storage and transportation.

The international plasma-derived product industry has long been in a state of oversupply. The main reason for this situation is the limited supply ability of international plasma-derived products and the large market demand, while the supply of plasma-derived product is insufficient. As the world’s largest demand market for plasma-derived products, China is one of the largest consumers and manufacturers of plasma-derived products in the world. In China, both blood products and plasma products are regarded as strategic resources, and China’s plasma extraction and processing technology has made great progress in recent decades and is rapidly expanding its production capacity, so that in the near future there will be more high-quality Chinese plasma products suppliers in the world, and “Chinese blood” will be delivered to the global medical market.